An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

Journal of Pain and Symptom Management

Volumn 46, Issue 2, 2013, Pages 207-218

  Johnson, Jeremy R ^a   Lossignol, Dominique ^b   Burnell Nugent, Mary ^c   Fallon, Marie T ^d  

^a The Shropshire and Mid Wales Hospice   (United Kingdom)

^b Association Hospitaliere de Brussels   (Belgium)

^c St Lukes' Hospice   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer; cannabinoid; delta 9 tetrahydrocannabinol; pain; THC CBD oromucosal spray

Indexed keywords

DIAMORPHINE; DICLOFENAC; DRONABINOL; KETAMINE; MORPHINE SULFATE; NABIXIMOLS; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; PETHIDINE; PLACEBO;

ADULT; ADVANCED CANCER; AEROSOL; ANALGESIA; ARTICLE; BONE CANCER; BREAST CANCER; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER PATIENT; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HEMATEMESIS; HUMAN; INSOMNIA; INTESTINE OBSTRUCTION; LUNG CANCER; MALE; MALIGNANT MESOTHELIOMA; MEMORY DISORDER; MULTICENTER STUDY; MYELOMA; NEUROPATHIC PAIN; OPEN STUDY; PROSTATE CANCER; RECTUM CANCER; SOMNOLENCE; TERMINAL DISEASE; TREATMENT DURATION; UTERINE CERVIX CARCINOMA; VOMITING; XEROSTOMIA;

EID: 84882452814     PISSN: 08853924     EISSN: 18736513     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2012.07.014     Document Type: Article

References (34)

1. World Health Organization International Agency for Research and Cancer. Globocan 2008. Cancer incidence and mortality worldwide in 2008. Available from http://globocan.iarc.fr. Accessed July 26, 2012.
2. J.J. Bonica The management of pain 2nd ed. 1990 Lea and Febiger Philadelphia, PA Available from www.painresearch.utah.edu/crc/CRCpage/cancer. html Accessed July 26, 2012
3. L.C. Goudas, R. Bloch, and M. Gialeli-Goudas The epidemiology of cancer pain Cancer Invest 23 2005 182 190
4. L.J. Kehl, D.T. Hamamoto, and P.W. Wacnik A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain Pain 1023 2003 175 186
5. World Health Organization Cancer pain relief with a guide to opioid availability 2nd ed. 1996 World Health Organization Geneva
6. A. Jacox, D.B. Carr, and R. Payne Management of cancer pain (AHCPR Clinical Practice Guidelines, No. 9) 1994 Agency for Health Care Policy and Research (AHCPR) Rockville, MD Available from http://www.ncbi.nlm.nih.gov/books/ NBK52307/ Accessed July 26, 2012
7. A.C. Howlett, F. Barth, and T.I. Bonner International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol Rev 54 2002 161 202
8. E. Ryberg, N. Larsson, and S. Sjogren The orphan receptor GPR55 is a novel cannabinoid receptor Br J Pharmacol 152 2007 984 986
9. R.G. Pertwee Cannabinoid receptors and pain Prog Neurobiol 63 2001 569 611
10. M. Begg, N. Dale, E. Llaudet, and A. Molleman Modulation of the release of endogenous adenosine by cannabinoids in the myenteric plexus-longitudinal muscle preparation of the guinea-pig ileum Br J Pharmacol 137 2002 1298 1304
11. R.G. Pertwee Cannabinoid pharmacology: the first 66 years Br J Pharmacol 147 2006 153 171
12. R. Noyes, S.F. Brunk, and D.A. Baram Analgesic effect of delta 9-tetrahydrocannabinol J Clin Pharmacol 15 1975 139 143
13. R. Noyes, S.F. Brunk, D.A. Avery, and A.C. Canter The analgesic properties of delta 9-tetrahydrocannabinol and codeine Clin Pharmacol Ther 18 1975 84 89
14. R.G. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors Pharmacol Ther 74 1997 129 180
15. E.B. Russo, and G.W. Guy A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med Hypotheses 66 2006 234 246
16. I. Bushlin, R. Rozenfeld, and L.A. Devi Cannabinoid-opioid interactions during neuropathic pain and analgesia Curr Opin Pharmacol 18 2010 80 86
17. I. Reche, J.A. Fuentes, and M. Ruiz-Gayo Potentiation of delta-9-tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors Eur J Pharmacol 318 1996 11 16
18. F.L. Smith, D. Cichewicz, Z.L. Martin, and S.P. Welch The enhancement of morphine antinociception in mice by delta-9-tetrahydrocannabinol Pharmacol Biochem Behav 60 1998 559 566
19. S.P. Welch, and D.L. Stevens Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine in mice J Pharmacol Exp Ther 262 1992 10 18
20. D.I. Abrams, P. Couey, S.B. Shade, M.E. Kelly, and N.L. Benowitz Cannabinoid-opioid interaction in chronic pain Nature 90 2011 844 853
21. T.J. Nurmikko, M.G. Serpell, and B. Hoggart Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial Pain 133 2007 210 220
22. D.J. Rog, T.J. Nurmikko, T. Friede, and C.A. Young Randomized controlled trial of cannabis based medicine in central pain due to multiple sclerosis Neurology 65 2005 812 819
23. D.T. Wade, C. Collin, C. Stott, and P. Duncombe Meta-analysis of the efficacy and safety of Sativex (nabiximols) on spasticity in people with multiple sclerosis Mult Scler 16 2010 707 714
24. I. Novotna A randomized, double-blind, placebo-controlled, parallel group, enriched design study of Sativex in subjects with symptoms of spasticity due to multiple sclerosis Eur J Neurol 18 2011 1122 1131
25. J.R. Johnson, M. Burnell-Nugent, and D. Lossignol Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain J Pain Symptom Manage 39 2010 167 179
26. S.D. Mathias, R.D. Crosby, and Y. Qian Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form J Support Oncol 9 2011 72 78
27. J.T. Maringwa, C. Quinten, and M. King Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials Support Care Cancer 19 2011 1753 1760
28. P. Glare Choice of opioids and the WHO ladder M. Davis, P. Glare, J. Hardy, Opioids in cancer pain 2005 Oxford University Press Oxford 221 234
29. C. Ripamonti, and E.D. Dickerson Strategies for the treatment of cancer pain in the new millennium Drugs 61 2001 955 977
30. D.L. Cichewicz, Z.L. Martin, F.L. Smith, and S.P. Welch Enhancement of mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis on receptor identification J Pharmacol Exp Ther 289 1999 859 867
31. R. Portenoy, E.D. Ganae-Motan, and S. Allende Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial J Pain 13 2012 438 449
32. R. Dawson, J.A. Spross, and E.S. Jablonski Probing the paradox of patients' satisfaction with inadequate pain management J Pain Symptom Manage 23 2002 211 220
33. J.T. Farrar, J.P. Young Jr., and L. LaMoreaux Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale Pain 94 2001 149 158
34. H.M. McCormack, D.J. Horne, and S. Sheather Clinical applications of visual analogue scales: a critical review Psychol Med 18 1988 1007 1019